Unknown

Dataset Information

0

Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics.


ABSTRACT: Caveolae are critical cell surface structures important in coordinated cell signaling and endocytosis. One of the major proteins of caveolae is caveolin 1 (Cav-1). Cellular levels of Cav-1 are associated with cancer progression. In prostate cancer cells, levels of Cav-1 are positively correlated with tumor progression and metastasis. Cav-1 can be secreted by prostate cancer cells into the microenvironment and triggers proliferation and anti-apoptosis of the tumor and tumor endothelial cells. Clinical studies have shown increased serum Cav-1 levels in patients with poor prognosis. In tissue culture and animal model experiments, blocking secreted Cav-1 by polyclonal antibodies inhibits tumor cell growth. Cav-1 is therefore a potential therapeutic target for prostate cancer treatment. In this study, we used Cav-1 knock-out mice as hosts to produce monoclonal anti-Cav-1 antibodies. A total of 11 hybridoma cell lines were selected for their ability to produce antibodies that bound GST-Cav-1 but not GST on glutathione-coated ELISA plates. Further screening with ELISAs using GST-Cav-1 fragments on GSH-coated plates classified these antibodies into four groups: N1-31 with five antibodies binds the far N-terminus between amino acids 1 and 31; N32-80 with three antibodies binds between amino acids 32 and 80; CSD with two antibodies potentially bind the scaffolding domain (amino acids 80-101); and Cav-1-C with 1 antibody binds parts of the C-terminal half. Binding affinities (Kd) of these antibodies to soluble Cav-1 ranged from 10(-11) to 10(-8) M. Binding competition experiments revealed that these antibodies recognized a total of six different epitopes on Cav-1. Potency of these antibodies to neutralize Cav-1-mediated signaling pathways in cultured cells and in animal models will be tested. A selected monoclonal antibody will then be humanized and be further developed into a potential anti-prostate cancer therapeutic.

SUBMITTER: Kuo SR 

PROVIDER: S-EPMC3326273 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics.

Kuo Shu-Ru SR   Tahir Salahaldin A SA   Park Sanghee S   Thompson Timothy C TC   Coffield Scott S   Frankel Arthur E AE   Liu Jen-Sing JS  

Hybridoma (2005) 20120401 2


Caveolae are critical cell surface structures important in coordinated cell signaling and endocytosis. One of the major proteins of caveolae is caveolin 1 (Cav-1). Cellular levels of Cav-1 are associated with cancer progression. In prostate cancer cells, levels of Cav-1 are positively correlated with tumor progression and metastasis. Cav-1 can be secreted by prostate cancer cells into the microenvironment and triggers proliferation and anti-apoptosis of the tumor and tumor endothelial cells. Cli  ...[more]

Similar Datasets

| S-EPMC4139012 | biostudies-literature
| S-EPMC8124690 | biostudies-literature
| S-EPMC8671520 | biostudies-literature
| S-EPMC3344278 | biostudies-literature
| S-EPMC6828728 | biostudies-literature
| S-EPMC3678432 | biostudies-literature
| S-EPMC3712731 | biostudies-literature
| S-EPMC3348872 | biostudies-literature
| S-EPMC3688259 | biostudies-literature
| S-EPMC4549361 | biostudies-literature